Also known as: Ozempic, Wegovy
Semaglutide is a synthetic peptide that functions as a GLP-1 receptor agonist, primarily categorized under fat loss and metabolic peptides. It mimics the action of the naturally occurring hormone glucagon-like peptide-1 (GLP-1), which plays a crucial role in glucose metabolism and appetite regulation. Originally developed for the treatment of type 2 diabetes, Semaglutide has gained attention for its potential applications in metabolic research and weight management.
Semaglutide works by binding to GLP-1 receptors in the body, leading to several physiological effects that contribute to its efficacy in metabolic regulation.
Upon activation of the GLP-1 receptors, Semaglutide enhances insulin secretion in response to elevated blood glucose levels, while simultaneously inhibiting glucagon release. This dual action helps to lower blood sugar levels. Additionally, it slows gastric emptying, which promotes a feeling of fullness and reduces appetite, making it a valuable tool in weight management and metabolic studies.
Semaglutide is a prominent peptide in metabolic research, particularly as a GLP-1 receptor agonist. Its mechanisms of action and observed effects make it a significant focus for studies related to weight management and metabolic health.
Last updated: Jan 8, 2026
Tirzepatide: What Dual Agonism Actually Does (2026 Research Guide)
Semaglutide: What the Clinical Data Actually Shows (2026 Research Guide)